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Case Report
AbstractMany molecular target agents are continuously administered at fixed dosages.Imatinib, which can control the growth of a gastrointestinal stromal tumor, isadministrated at 400 mg/day. However, many patients cannot continue treatmentbecause of adverse events, such as neutropenia. To obtain the best therapeuticresponse while maintaining quality of life, individualization should be considered.Study participants were gastrointestinal stromal tumor patients who requiredtreatment with imatinib. Therapeutic drug monitoring was conducted usinghigh-performance liquid chromatography. In our study, the trough (lowest)concentration that a drug reaches before the next dose is administered differedamong patients. The grades of adverse events also differed individually. Moreover,the dosage that was necessary to shrink gastrointestinal stromal tumor differed incases by cases. Dosage was modified according to the balance between bloodconcentration and therapeutic responses in order to minimize adverse events forindividual patients, and to maximize the effect as the responses differed amongpatients. It was shown that based on therapeutic drug monitoring,individualization enabled the patients who may not normally continue the typicaltreatment to tolerate imatinib. According to the therapeutic drug monitoring,individualization of dosage of imatinib could improve the patients’ outcomes inboth ends, therapeutic and adeverse responses.
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1. IntroductionIndividualization of cancer chemotherapy with cytotoxicagents for solid tumors is a very important issue. Dosageis practically decided using the individual body surfacearea of the patient in many cases. Continuation oftreatment and/or adjustment of dosage are judged bythe evaluation of therapeutic outcome and the grading ofadverse events according to Response EvaluationCriteria in Solid Tumors (RECIST) and CommonTerminology Criteria for Adverse Events (CTC-AE),respectively. Therapeutic drug monitoring (TDM) couldoffer helpful information related to cancerchemotherapy as well as the anti-microbial efficacy ofantibiotics such as vancomycin1 or lithium salts2 formajor depressive disorder1. Nonetheless, TDM ofmethotrexate is only covered by medical insurance as acytotoxic agent.3 Many molecular targeted agents havebeen approved successively in the 21st century. Some ofthese drugs are administered on the basis of the
patients’ weight, but many of them are given at a fixeddosage. Examples of such drugs include sorafenib forhepatocellular carcinoma4 and sunitinib for renal cellcarcinoma5.A gastrointestinal stromal tumor (GIST) is derived fromthe intestinal smooth muscle pacemaker cell, known asthe Cajal cell; typically, it results from gain-of-functionmutations in the KIT or platelet-derived growth factor
receptor α (PDGFRA) genes.6 Imatinib is a tyrosinekinase inhibitor targeting KIT and PDGFRA proteins andis approved for advanced and post-operative patients, ahigh-risk group of GIST.7 Imatinib for GIST isadministered at a fixed dosage of 400 mg/day. MonthlyTDM for imatinib has recently been covered by medicalinsurance in Japan. The blood concentration of imatinibis measured by liquid chromatography-tandem massspectrometry8 or high-performance liquid
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chromatography (HPLC)9. The purpose of TDM is toadjust the blood concentration of imatinib within thetherapeutic window (TW). TW is the value between theminimal effective concentration (MEC) and the minimaltoxic concentration (MTC). It is important to be aware ofTW to minimize the adverse effects and maximize thetherapeutic effect. Therefore, it is necessary to clarify thepharmacodynamics (PD) and pharmacokinetics (PK) ofimatinib. However, the therapeutic effects and adverseevents associated with imatinib differ among patients,and TW ought to be determined individually. We presenta cohort, where individualization using TDM of imatinibwas successfully applied for GIST. We consider furtherapplication of TDM for individualization through thisgroup of individuals.
2. Methods/Case PresentationThe blood concentration of imatinib was examined usingHPLC, as established by Miura.9 To detect the troughvalue (Ctrough), samples were obtained in the morningbefore administration of imatinib. As the necessaryvolume for TDM is 0.3 mL, a routine blood test issufficient. Study participants were advanced or
post-operative GIST patients who required treatmentwith imatinib and who visited the Department of ClinicalOncology, Akita University Hospital from August 2014 toDecember 2015. All participants agreed with thisanalysis and publication; written informed consent wasobtained. Evaluation of the therapeutic response wasconducted using RECIST, version 1.1. The grade ofadverse events was judged using CTC-AE v4.0.
3. ResultsWe applied TDM of imatinib for 4 cases of GIST. Clinicalcharacteristics and the therapeutic courses aresummarized in Table 1.Case 1 was a 41-year old female with operated gastricGIST, peritonitis carcinomatosa (PC) and livermetastasis. Liver metastasis could be controlled byradiofrequency ablation (RFA). Imatinib wasadministered at 400 mg /day for PC. PC was controlledfor 12 months, and there were no adverse eventsobserved. The Ctrough values ranged from 1,960 to 2,120ng/mL (Figure 1).
Table 1: Characters of the participants
Case
#
Sex/ Age Diagnosis(primary )(meta) KITMutation Treat Dosageof ima(mg) BestResponse AE(Gr3) Ctrough(ng/ mL )1 F/ 41 ▶Gastric▶PC
▶Liver No (wild) ▶ surg▶ ima▶ RFA ▶ 400 ▶SD No ▶ 1,960- 2,1202 M/ 48 ▶Mesenteric▶PC (rec) Ex 9,codon 504,6-bpinsertion
▶ surg/ima

























– 654F; female, M; male, PC; peritonitis carcinomatosa, Ex; Exon, Surg; surgery, ima; imatinib, RFA; radio frequency ablation, TTP;time to progression, AE; adverse event, ND; not determined, SD; stable disease, PR; partial response, neu; neutropenia,* 100 mg of ima at every 2 day, Int; intermittent treatment
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Figure 1: Correlation between imatinib administration dosage and the Cthrough level.Case 1 (open circle), Case 2 (closed rectangle), Case 3 (open rectangle) and Case 4 (closed circle)
Figure 2: Intermittent administration with imatinib for treating Case 4. (A) Weekly treatment schedule. Ima; imatinib, G-CSF;granulocyte-colony stimulating factor; (B) Evaluation of the target lesion (PC nodules) by CT imaging
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Case 2 was a 48-year old male with resected mesentericGIST. After completion of adjuvant chemotherapy withimatinib, PC nodules recurred. Administration ofimatinib at 400 mg/day could control the PC nodules for10 months. The best response observed was a partialresponse. No adverse events were observed. The Ctroughvalues ranged from 252 to 659 ng/mL (Figure 1).Case 3 was a 47-year old female with resected gastricGIST, considered high-risk. Adjuvant chemotherapy withimatinib was started, but a dose of 400 mg/day couldnot be continued because of the frequent occurrence ofgrade 3 neutropenia. Consequently, the dosage wasreduced to 300 mg/day. This dosage wasbetter-tolerated despite occasional grade 3 neutropenia.The Ctrough values at 400 mg/day and 300 mg/day were785 and 460 ng/mL, respectively (Figure 1). During 24months of this regimen, no recurrences were apparent.Case 4 was a 71-year old male with recurrence of livermetastasis after resected distal gastric GIST. He wasreferred from another hospital due to imatinibtreatment difficulties caused by frequent neutropenia.First, imatinib was started at a dosage of 300 mg/day toconfirm sensitivity of imatinib against liver metastasis.Positron emission tomography-computed tomography(PET-CT) indicated the disappearance of 18fluorodeoxyglucose uptake in the liver, 41 days after initiation ofimatinib (before treatment; SUV max = 3.9–4.1).However, at day 23, grade 3 neutropenia becameapparent and was prolonged. Consequently, we reducedthe dosage on a step-by-step gradient to 200 and to 100mg/day, but the patient continued to experience grade 3neutropenia. In this case, the Ctrough levels were notdecreased and linear. The values were 709, 565 and 593ng/mL at 300, 200 and 100 mg/day administration,respectively (Figure 1). Furthermore, when imatinib wasadministered at 100 mg every two days, the Ctrough levelwas reduced to 54 ng/mL. We found that one-dayinterruption reduced the blood concentration below 10% of the Ctrough level.As the administration of imatinib was difficult and thetarget lesion existed only in the liver, we selected RFAfor the liver metastasis. RFA could control the livertargets, but 2.5 months after RFA, gastrointestinalobstruction occurred due to an intra-abdominaldisseminated tumor (6 cm in diameter at its largest size)near the esophageal-cardiac junction. Therefore, wedecided to intermittently treat this situation withimatinib. As 300 mg/day of imatinib was effective,imatinib was administered for 3 successive days andwas stopped from day 4 to day 7. The Ctrough level at day4 was 654 ng/mL and at day 8 had reduced to 60 ng/mL(Figure 1).However, as neutropenia was still present,granulocyte-colony stimulating factor was administeredon day 5. We proposed this intermittent treatment to the
patient and obtained informed consent (Figure 2).Gastrointestinal obstruction improved at day 7 afterinitiation of intermittent treatment, and an approximate50% reduction was confirmed by CT a month afterinitiation. This treatment was continued without anyadverse events, and he still has partial response at 9.5months.
4. DiscussionThe Cthrough level of imatinib ranges from 414 to 4,182ng/mL at a dosage of 400 mg/day.10 In our studyparticipants, this value ranged from 252 to 2,120 ng/mL.These data indicate that PK of imatinib differs amongindividuals. It is recommended that the targetconcentration of imatinib for GIST was more than 1,100ng/mL (Ctrough).11 However, the therapeutic responsewas observed at levels below 1,000 ng/mL in someother studies as well as in ours. Furthermore, the gradeof adverse events differed from patient to patient usingthe same dosage. These facts indicated that PD ofimatinib also differs between patients. Consequently, thevalidation of individual TW of imatinib is very difficult.12There might be influential factors affecting TW. Forexample, breast cancer resistance protein (BCRP)contributes to the excretion of imatinib metabolites tothe bile duct.13 A BCRP gene (421 C>A) single nucleotidepolymorphism, which is found in approximately 45% ofthe normal Japanese population14, reduces BCRPfunction15. Consequently, the concentration of imatinibin patients bearing this mutation might increase. Inaddition, the effect of imatinib on GIST itself depends on
KIT or PDGFRA mutations.16 Besides these examples,there might be other unknown factors that can affect thetherapeutic effects and/or the adverse events ofimatinib.12 The correlation between the Cthrough level andthe therapeutic effect and/or the correlation betweenthe Cthrough level and the adverse event should bemonitored using TDM. This would optimize the effects ofimatinib. Accordingly, we suggest individualization ofthe drug dosage.
5. ConclusionTherapeutic drug monitoring of imatinib for GIST isinformative and beneficial method to the patients whocannot continue the treatment due to the adverse eventsby measuring of the individual therapeutic window ofimatinib.
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